NDF-RT Public Edition Release notes ----------------------------------------------------------------- May 2008 NDF-RT (version name 2008.05.13) This release of NDF-RT Public Edition contains 77 new concepts: 44 added to the EXT hierarchy, 13 added to the PE hierarchy, 18 added to the MoA hierarchy, and 2 added to the Chemical/Ingredient hierarchy. Part of the large new concepts count is due to a reorganization of the Nervous System PE hierarchy. The changed concepts count this month is due to 4 concept name changes: Chemical Structures for Pharmacologic Classification [Chemical/Ingredient] was changed to Chemical Classes for Pharmacologic Classification [Chemical/Ingredient]; Neurological & Neuromuscular System Activity Alteration [PE] was changed to Nervous System Activity Alteration [PE]; NMDA Receptor Antagonist [MoA] was made plural; and Striated Muscle Alteration [PE] was changed to Striated Muscle Metabolic Alteration [PE]. 135,999 total concepts 77 new concepts 4 changed concepts 0 concepts removed ----------------------------------------------------------------- April 2008 NDF-RT (version name 2008.04.08) This release of NDF-RT Public Edition contains 10 new concepts: 24 added to the EXT hierarchy, 7 added to the PE hierarchy, and 4 added to the MoA hierarchy. The changed concepts count this month is due to two concept name changes. The old concept name Alcohol Dehyrogenase Inhibitors [MoA] was changed to include "Dehydrogenase", the correct spelling. The concept Angiotensin-Converting Enzyme Inhibitors [MoA] was changed to make "-Converting" lowercase for consistency with other hyphenated NDF-RT concept names. 135,922 total concepts 35 new concepts 2 changed concepts 0 concepts removed ----------------------------------------------------------------- March 2008 NDF-RT (version name 2008.03.11) This release of NDF-RT Public Edition contains 10 new concepts: 8 added to the EXT hierarchy, and 2 added to the MoA hierarchy. The changed concepts count this month is due to concept name changes. Instances of the acronym "GNRH" in 4 existing concept names in the PE hierarchy were changed to "GnRH". In addition, the following changes to EXT concept names were made, with the former concept names retained as synonyms: Angiotensin 2 Receptor Blocker [EXT], Phosphodiesterase 3 Inhibitor [EXT], and Phosphodiesterase 5 Inhibitor [EXT] were renamed to include Roman numerals, to replicate the original pharmacologic class requested phrases; Greek letters in the concept names Interferon Alpha [EXT] and Interferon Gamma [EXT] were lowercased; and GnRH Secretion Inhibitor [EXT] was changed to reflect the fully-specified name Gonadotropin Releasing Hormone Secretion Inhibitor [EXT]. 135,887 total concepts 10 new concepts 12 changed concepts 0 concepts removed ----------------------------------------------------------------- February 2008 NDF-RT (version name 2008.02.12) This release of NDF-RT Public Edition contains 41 new concepts: 13 added to the EXT hierarchy, 11 added to the MoA hierarchy, and 17 added to the PE hierarchy. The changed concepts count is due to subtree reorganization under the new concept Autonomic Nervous System Activity Alteration [PE]. In addition to this hierarchy reorganization, a second parent was given to any legacy neurotransmitter-specific sympathetic/parasympathetic activity concepts in the new subtree. Finally, a number of concept names containing "Norepinepherine" were changed to reflect the correct spelling. 135,877 total concepts 41 new concepts 37 changed concepts 2 concepts removed ----------------------------------------------------------------- January 2008 NDF-RT (version name 2008.01.08) This release of NDF-RT Public Edition contains changes reflecting decisions made at the November 2007 SPL IEP face-to-face meeting. The former Additional FDA Pharmacologic Classes for SPL hierarchy has been renamed to "External Pharmacologic Classes", and now contains new concepts whose names replicate each pharmacologic class string received. These concepts are mapped via role relationships to appropriate MoA, PE, or Chemical/Ingredient concepts. All concepts in this hierarchy have the tag [EXT] appended to their names, replacing the former [FDA SPL] tag. In addition to new concepts created manually in this hierarchy to reflect recent SPL IEP decisions, 61 concepts were added programmatically from former FDA_SPL_Name property values that existed for those NDF-RT concepts considered to be one-to-one maps to SPL pharmacologic class phrases. These EXT concept names exactly replicate the former FDA_SPL_Name property values. All existing FDA_SPL_Name property values were then removed, and as this property will no longer be used, the property type has been removed entirely from NDF-RT. In addition to these 61 concepts added programmatically, there were 72 new concepts added to the EXT hierarchy based on submissions from the Antimicrobial/Transplant/Hematology FDA list. Other new concepts included 6 added to the Chemical/Ingredient hierarchy, 5 added to the PE hierarchy, and 11 added to the MoA hierarchy. The changed concepts count is due to 14 MoA concepts, which were renamed for consistency to include "Activity" instead of "Agents", "Preparations", or "Scavengers", and one concept whose former name contained an incorrect spelling. Additionally, 29 existing concepts in the EXT (formerly Additional FDA Pharmacologic Classes for SPL) hierarchy were renamed, removing the [FDA SPL] tag and adding the new [EXT] tag. The concept Influenza Neuraminidase Inhibitors [MoA] was retired. The newly-created concept Influenza Neuraminidase Inhibitor [EXT] retains this former concept's NUI. 135,838 total concepts 145 new concepts 43 changed concepts 1 concept removed ----------------------------------------------------------------- November 2007 NDF-RT (version name 2007.11.13) This release of NDF-RT Public Edition contains 11 new concepts: 4 added in the Additional FDA Pharmacologic Classes for SPL list, 6 added to the MoA hierarchy, and 1 added to the Chemical/Ingredient hierarchy. The changed concepts count is due to two renamed MoA concepts, Tumor Necrosis Factor Alpha Receptor Blocking Activity [MoA], and Tumor Necrosis Factor Beta Receptor Blocking Activity [MoA]. 135,684 total concepts 11 new concepts 2 changed concepts 0 concepts removed ----------------------------------------------------------------- October 2007 NDF-RT (version name 2007.10.09) This release of NDF-RT Public Edition contains 17 new concepts: 8 added in the Additional FDA Pharmacologic Classes for SPL list, 1 added to Supplementary Chemicals [Chemical/Ingredient], 1 added to the PE hierarchy, 5 added to the MoA hierarchy, and 2 added to the Chemical/Ingredient hierarchy. An official NDF-RT SPL IEP decision was made to add a second FDA_SPL_Name, beta-Adrenergic Receptor Inhibitor, to the concept Adrenergic beta-Antagonists [MoA], which was mapped to both the New Products pharm. class phrase with the same string and the Cardiac/Renal submission beta-adrenergic blocker. Going forward, this approach will ONLY be used when the FDA_SPL_Name values are true synonyms. 135,673 total concepts 17 new concepts 0 changed concepts 0 concepts removed ----------------------------------------------------------------- August/September 2007 NDF-RT (version name 2007.08.31) This full release of NDF-RT Public Edition contains the new "Additional FDA Pharmacologic Classes for SPL" list under "Pharmaceutical Preparations". Its 16 assigned children were created in response to requests for concepts to support the FDA Structured Product Labeling (SPL) initiative. Concepts in this group represent specific requests for SPL Pharmacologic Class phrases that can not be represented by a single new or existing MOA, PE or CS NDF-RT concept. This includes phrases that represent therapeutic intent as defined by the FDA SPL initiative, as well as those represented by the concatenation of multiple NDF-RT concepts, and in rare cases ideas that did not fit elsewhere within NDF-RT. None of the concepts in this new group are listed in the MOA, PE or CS SPL files published separately but many have defining role relationships to one or more MOA, PE and CS concepts. The changed concepts count includes concepts changed for remodeling of the Nucleic Acid Synthesis Inhibitors [MoA], Protease Inhibitors [MoA], and Kinase Inhibitors [MoA] subtrees, as well as concepts affected by new FDA_SPL_Name algorithm, and two concepts renamed due to misspellings. Fms-like tyrosine kinase (FLT) Inhibitors [MoA] was removed after determining that it was not used as a role value for NDF-RT drug modeling. 135,656 total concepts 17 new concepts 78 changed concepts 1 concept removed ----------------------------------------------------------------- July 2007 NDF-RT (version name 2007.07.10) This Full release of NDF-RT Public Edition contains no added concepts based on FDA submissions for SPL. Changes in this version of NDF-RT occurred solely due to a few changes and 85 additional mappings of NDF-RT Disease concepts that already had at least one existing SNOMED CT mapping. None of these were on the current SPL Problem List (Jan. 2007). These changes resulted in the creation of at least one additional map from that Disease concept to a SNOMED CT concept on the SPL Problem List. A map (recorded as a property on the concept) to a SNOMED CT concept on the SPL Problem List will now be called the SPL_Problem_List_Mapping_ID. In addition, the existing SNOMED_ID property was renamed to SNOMED_Mapping_ID. This final change resulted in the large changed concept count. 135,640 total concepts 0 new concepts 2478 changed concepts ----------------------------------------------------------------- June 2007 NDF-RT (version name 2007.06.12) This Full release of NDF-RT Public Edition contains changes derived from SPL Pharmacologic Class requirements plus changes derived from a re-synchronization of the Chemical/Ingredient hierarchy with the current version of MeSH (2007). 135,640 total current concepts 324 new concepts 33 changed concepts 21 deprecated concepts (reflects semantic duplicates noted either due to formal SPL decisions or MeSH refresh QA process. Prior meanings and NUIs of these concepts are attributed to existing NDF-RT concepts.) A substantial reduction in the number of synonyms is reflected in this release due to the improved accuracy of synonym assignment based on UMLS Metathesaurus. Removed synonyms were all from the Chemical/Ingredient hierarchy. Chemicals and Ingredients concepts were derived from 2007 ASCII MeSH files. ----------------------------------------------------------------- May 2007 NDF-RT (version name 2007.05.08) Starting with the May 2007 release a new property has been created: FDA_SPL_Name. This property will only be added to concepts when there is requirement for a concept representation (IE: a term name) preferred for SPL use that is not the existing “preferred name” for the concept. The value of the FDA_SPL_Name property may be an existing synonym, or it may be a new term representation. If it is new, it will only be additionally added as a synonym for concepts NOT derived from MeSH. This was done to keep synonyms algorithmically consistent with the UMLS MeSH synonym list for that concept (as noted above.) Only concepts requiring these additions will carry this property. This means that any SPL user must determine if that property exists for a concept and use the value as the concept preferred name. This Full release of NDF-RT Public Edition contains only a few changes modeled and approved by the ICCB committee. 135,337 total current concepts 6 new concepts 1 changed concept 1 retired concept Chemicals and ingredient concepts were derived from MeSH 2006 (2006_05_01) ----------------------------------------------------------------- April 2007 NDF-RT (version name 2007.04.10) This Full release of NDF-RT Public Edition contains only a few changes modeled and approved by the ICCB committee. 135,332 total current concepts 10 new concepts 1 changed concept 1 retired concept Chemicals and ingredient concepts were derived from MeSH 2006 (2006_05_01) ----------------------------------------------------- March 2007 NDF-RT (version name 2007.03.13) As of the March, 2007, the provision of NDF-RT content outside the VA system will not include elements deemed only of value to internal VA operations. This "extract" will be known as the NDF-RT Public Edition and will contain all of the core NDF-RT concepts that existed in previous releases and all concept NUIs will remain unchanged. In essence the Public Edition only removes selected VA-specific properties, qualifiers, associations and a few Kinds that represented information required for unique internal VA activities. All Roles remain unchanged. These changes are expected to have no impact on non-VA use of the NDF-RT. Listed below are the changes implemented beginning with this release. *********************************************** **ELEMENTS PRESERVED IN NDF-RT PUBLIC EDITION** *********************************************** NDF_KIND {formerly DRUG_KIND} INGREDIENT_KIND MECHANISM_OF_ACTION_KIND PHYSIOLOGIC_EFFECT_KIND PHARMACOKINETICS_KIND DISEASE_KIND RECIP_STRUCTURES_KIND RXNORM_DOSE_FORM_KIND Source -> Target has_Ingredient NDF_KIND --> INGREDIENT_KIND CI_ChemClass NDF_KIND --> INGREDIENT_KIND metabolized_by NDF_KIND --> INGREDIENT_KIND has_active_metabolites NDF_KIND --> INGREDIENT_KIND effect_may_be_inhibited_by NDF_KIND --> NDF_KIND metabolized_by_recip_structure NDF_KIND --> RECIP_STRUCTURES_KIND gene_encodes_for RECIP_STRUCTURES_KIND --> INGREDIENT_KIND gene_has_variant RECIP_STRUCTURES_KIND --> RECIP_STRUCTURES_KIND gene_encodes_for_enzyme RECIP_STRUCTURES_KIND --> RECIP_STRUCTURES_KIND has_MoA NDF_KIND --> MECHANISM_OF_ACTION_KIND CI_MoA NDF_KIND --> MECHANISM_OF_ACTION_KIND has_PE NDF_KIND --> PHYSIOLOGIC_EFFECT_KIND CI_PE NDF_KIND --> PHYSIOLOGIC_EFFECT_KIND has_PK NDF_KIND --> PHARMACOKINETICS_KIND site_of_metabolism NDF_KIND --> PHARMACOKINETICS_KIND may_treat NDF_KIND --> DISEASE_KIND may_prevent NDF_KIND --> DISEASE_KIND may_diagnose NDF_KIND --> DISEASE_KIND induces NDF_KIND --> DISEASE_KIND CI_with NDF_KIND --> DISEASE_KIND has_DoseForm NDF_KIND --> RXNORM_DOSE_FORM_KIND Heading_Mapped_To INGREDIENT_KIND --> INGREDIENT_KIND VA_Product_Component NDF_KIND --> NDF_KIND VA_Secondary_Drug_Class NDF_KIND --> NDF_KIND VA_Strength VA_Unit NUI Display_Name Synonym Level Status Status_Change_Date Review_Status MeSH_Name MeSH_UI Included_MeSH_UIs MeSH_Definition MeSH_Pharmacologic_Action NCI_Preferred_Term RxNorm_CUI RxNorm_Code RxNorm_Name RxNorm_Preferred_Translation_Term SNOMED_ID UNII UMLS_CUI UMLS_Semantic_Type UMLS_Preferred_Translation_Term VUID VA_Class_Description VA_Class_Code VA_Class_Type VA_CS_Federal_Schedule VA_Manufacturer_Code VA_National_Formulary_Name VA_NDC VA_NDF_Type VA_Product_Code VA_Package_Code VA_Print_Name VA_RxOtc_Indicator VA_Strength VA_Trade_Name VA_Units VA_UPN Date Status VUID *********************************************************** **VA-SPECIFIC ELEMENTS REMOVED FROM NDF-RT PUBLIC EDITION** *********************************************************** EXTERNAL_REFERENCE_KIND VA_DISPENSE_UNITS_KIND VA_DOSE_FORMS_KIND VA_DRUG_INTERACTION_KIND VA_DRUG_MANUFACTURER_KIND VA_DRUG_UNIT_KIND VA_NATIONAL_FORMULARY_RESTRICTION_KIND VA_PACKAGE_SIZE_KIND VA_PACKAGE_TYPE_KIND VA_ROUTE_OF_ADMINISTRATION_KIND External_Dispense_Unit External_Dose_Form External_Package_Size External_Package_Type External_ROA VA_Dispense_Units VA_Dose_Form VA_Dose_Form_Units VA_Drug_Manufacturer VA_Ingredient_1 VA_Ingredient_2 VA_National_Formulary_Restriction VA_Package_Size VA_Package_Type VA_ROA FILE IEN PACKAGE Search_Name Last_Reviewed Reviewed_By Comment Alert VA_Abbreviation VA_Discontinue VA_Dispense_Units_Per_Dose VA_Dose_Form_Print_Name VA_Drug_Identifier VA_DSS_Number VA_Exclude_Drug_Interaction_Check VA_File VA_IvFlag VA_Max_Cumulative_Dose VA_Max_Daily_Dose VA_Max_Single_Dose VA_Min_Daily_Dose VA_Min_Single_Dose VA_Nationally_Entered VA_National_Formulary_Indicator VA_NDT_XML VA_Package_Use VA_Product_Identifier VA_Severity VA_Single_or_Multi_Source_Product VA_Total_Indexes VA_Transaction_History VA_Transmit_to_CMOP VA_User_Lock VA_Workflow_Comment VA_Workflow_Status User Name VA_Class_Description_Line VA_File VA_IEN VA_PACKAGE NDF-RT Public Edition Release notes Created on 3/23/07